Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CM06 | ISIN: US6412881053 | Ticker-Symbol:
NASDAQ
28.03.24
20:41 Uhr
13,180 US-Dollar
-0,450
-3,30 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEUROPACE INC Chart 1 Jahr
5-Tage-Chart
NEUROPACE INC 5-Tage-Chart

Aktuelle News zur NEUROPACE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiNeuroPace, Inc: NeuroPace to Present at the Needham 23rd Annual Healthcare Conference1
11.03.NeuroPace shares target lifted to $17 by JPMorgan3
06.03.Neuropace Inc reports results for the quarter ended in December - Earnings Summary1
05.03.NeuroPace Inc - S-8, Securities to be offered to employees in employee benefit plans1
05.03.NeuroPace Inc - 10-K, Annual Report1
05.03.Recap: NeuroPace Q4 Earnings1
05.03.NeuroPace, Inc.: NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million185-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 -- -- Provides full-year 2024 revenue guidance...
► Artikel lesen
05.03.NeuroPace Inc - 8-K, Current Report1
22.02.A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts1
15.02.NeuroPace, Inc: NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024-
07.02.NeuroPace Inc - 8-K, Current Report1
08.01.NeuroPace stock soars on upbeat Q4 revenue guidance1
08.01.NeuroPace Inc - 8-K, Current Report1
08.01.NeuroPace, Inc: NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates298Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023 Company begins 2024 with cash balance...
► Artikel lesen
21.12.23NeuroPace, Inc.: NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study1.142NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently indicated...
► Artikel lesen
19.12.23NeuroPace, Inc.: NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference1
04.12.23NeuroPace, Inc.: NeuroPace to Leverage the Power of its RNS System's Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration146First of its kind, multi-year collaboration leverages RNS System's data to track responses of implanted RNS System patients enrolled in a biotechnology company's clinical trial In strategic data collaboration...
► Artikel lesen
04.12.23NeuroPace Inc - 8-K, Current Report1
04.12.23Expert Ratings for NeuroPace1
01.12.23NeuroPace, Inc.: NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting1
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1